Intelligent α-Cyclodextrin-Based Nanomachines Co-loading Lenalidomide and Au@TPE for NIR-I-Light Programmed
Ying Tian1, Jingxuan Xu1, Qianqian Che1
1School of Food Science and Engineering, State Key Laboratory of Biobased Material and Green Papermaking, School of Materials Science and Engineering, Qilu University of Technology, Shandong Academy of Sciences, Jinan 250353, China.
ACS Applied Bio Materials
|April 7, 2026
Summary
This study introduces a novel nanomachine for breast cancer treatment, combining photothermal therapy with immunotherapy. This dual-action approach enhances therapeutic efficacy and minimizes side effects for precision oncology.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Malignant tumors pose a significant threat to human health.
- Micro/nanomachines offer minimally invasive advantages for cancer therapy.
- Current therapies require improvement in targeted delivery and efficacy.
Purpose of the Study:
- To design and evaluate an α-cyclodextrin-based nanomachine (αALN) for combined photothermal therapy (PTT) and immunotherapy.
- To achieve targeted delivery of photothermal agents and immunomodulatory drugs to tumor sites.
- To enhance breast cancer treatment through synergistic PTT and immunotherapy.
Main Methods:
- Development of an α-cyclodextrin-based nanomachine (αALN) encapsulating Au@TPE nanoparticles.
- Integration of the immunomodulatory drug lenalidomide into the αALN system.
- In vivo evaluation of αALN for targeted delivery, PTT, and immune response activation in breast cancer models.
Main Results:
- αALN demonstrated high loading capacity for Au@TPE and effective targeted delivery to tumors.
- The nanomachine exhibited excellent photothermal conversion efficiency and stability.
- Combined PTT and lenalidomide-mediated immunotherapy significantly enhanced anti-tumor immune responses and therapeutic efficacy in breast cancer.
Conclusions:
- The developed αALN nanomachine provides a promising strategy for precision oncology.
- Combining PTT with lenalidomide-mediated immunotherapy offers a synergistic approach to enhance breast cancer treatment.
- αALN shows potential for minimizing side effects on healthy tissues due to its targeted delivery and low intrinsic toxicity.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K